NASDAQ:MGTX MeiraGTx (MGTX) Stock Price, News & Analysis $5.36 +0.26 (+5.10%) Closing price 04:00 PM EasternExtended Trading$5.08 -0.29 (-5.32%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About MeiraGTx Stock (NASDAQ:MGTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MeiraGTx alerts:Sign Up Key Stats Today's Range$5.08▼$5.3850-Day Range$4.64▼$7.7952-Week Range$3.85▼$8.75Volume340,916 shsAverage Volume363,889 shsMarket Capitalization$430.76 millionP/E RatioN/ADividend YieldN/APrice Target$24.00Consensus RatingBuy Company OverviewMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Read More… MeiraGTx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreMGTX MarketRank™: MeiraGTx scored higher than 89% of companies evaluated by MarketBeat, and ranked 109th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMeiraGTx has only been the subject of 2 research reports in the past 90 days.Read more about MeiraGTx's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MeiraGTx are expected to grow in the coming year, from ($1.48) to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MeiraGTx is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MeiraGTx is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioMeiraGTx has a PEG Ratio of 0.37. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioMeiraGTx has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MeiraGTx's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.95% of the float of MeiraGTx has been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in MeiraGTx has recently increased by 16.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMeiraGTx does not currently pay a dividend.Dividend GrowthMeiraGTx does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.54 Percentage of Shares Shorted3.95% of the float of MeiraGTx has been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in MeiraGTx has recently increased by 16.94%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.63 News SentimentMeiraGTx has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for MeiraGTx this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for MGTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $397,650.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of MeiraGTx is held by insiders.Percentage Held by Institutions67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MeiraGTx's insider trading history. Receive MGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTX Stock News HeadlinesFY2025 EPS Estimates for MeiraGTx Lowered by Chardan CapitalMay 20, 2025 | americanbankingnews.comMeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual MeetingMay 13, 2025 | globenewswire.comHow Trade Wars Are Creating Fresh Opportunities for InvestorsTariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”May 29, 2025 | Darwin (Ad)MeiraGTx Reports First Quarter 2025 Financial and Operational ResultsMay 13, 2025 | globenewswire.comFDA grants RMAT status to MeiraGTx’s Parkinson’s treatmentMay 11, 2025 | investing.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s DiseaseMay 9, 2025 | finance.yahoo.comMeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's DiseaseMay 9, 2025 | globenewswire.comCone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and moreApril 29, 2025 | globenewswire.comSee More Headlines MGTX Stock Analysis - Frequently Asked Questions How have MGTX shares performed this year? MeiraGTx's stock was trading at $6.09 at the beginning of the year. Since then, MGTX stock has decreased by 13.7% and is now trading at $5.2550. View the best growth stocks for 2025 here. How were MeiraGTx's earnings last quarter? MeiraGTx Holdings plc (NASDAQ:MGTX) announced its earnings results on Tuesday, May, 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.13. The business had revenue of $1.93 million for the quarter, compared to the consensus estimate of $4.44 million. MeiraGTx had a negative net margin of 633.05% and a negative trailing twelve-month return on equity of 146.38%. When did MeiraGTx IPO? MeiraGTx (MGTX) raised $75 million in an initial public offering on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager. Who are MeiraGTx's major shareholders? MeiraGTx's top institutional investors include Adage Capital Partners GP L.L.C. (7.05%), 683 Capital Management LLC (3.22%), Woodline Partners LP (1.01%) and Erste Asset Management GmbH (0.99%). Insiders that own company stock include Perceptive Advisors Llc, Alexandria Forbes, Richard Giroux and Robert K Zeldin. View institutional ownership trends. How do I buy shares of MeiraGTx? Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MeiraGTx own? Based on aggregate information from My MarketBeat watchlists, some other companies that MeiraGTx investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Moderna (MRNA). Company Calendar Last Earnings5/13/2025Today5/29/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGTX CIK1735438 Webwww.meiragtx.com Phone(646) 860-7985FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$35.00 Low Stock Price Target$13.00 Potential Upside/Downside+370.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth0.37Net Income-$84.03 million Net Margins-633.05% Pretax Margin-633.05% Return on Equity-146.38% Return on Assets-53.05% Debt Debt-to-Equity Ratio0.86 Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual Sales$34.51 million Price / Sales11.88 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book2.35Miscellaneous Outstanding Shares80,365,000Free Float71,588,000Market Cap$409.86 million OptionableOptionable Beta1.30 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:MGTX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.